research Hair Graying and Loss Induced by Imatinib Mesylate
A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.
Search
for
Sort by
Research
240-270 / 1000+ results 
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
research Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
research Frontal Fibrosing Alopecia: A Disease Fascinating for the Researcher, Disappointing for the Clinician and Distressing for the Patient
Frontal Fibrosing Alopecia is a poorly understood condition that is hard to treat and causes distressing hair loss.
research Acne Exacerbation After Tofacitinib Treatment for Alopecia Areata
Tofacitinib treatment for hair loss may worsen acne.
research Nilotinib-Induced Generalized Keratosis Pilaris: Report of a Rare Case
Nilotinib can cause generalized keratosis pilaris.
research Erosive Pustular Dermatosis of the Scalp Induced by Gefitinib: Case and Review of the Literature
An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.
research Childhood Alopecia Areata: An Overview of Treatment and Recent Patents
Childhood Alopecia Areata causes hair loss and requires varied treatments, with psychological support being crucial.
research What’s New in Hair Loss
New treatments for hair loss show promise, but require more research on long-term effects and proper dosing.
research Biologics in the Management of Childhood Atopic Dermatitis
Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
research Tofacitinib as a Pragmatic Treatment Choice for Alopecia Areata: A Retrospective Review
Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
research The Role of Tofacitinib in the Management of Alopecia Totalis
Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib
Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.
research Unusual Progression of Renal Cell Carcinoma with Carcinomatosis Peritoneii and Krukenberg Tumor and Alopecia with Sunitinib Therapy in a Young Female
A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.
research Upadacitinib for Management of Recalcitrant Alopecia Areata: A Retrospective Case Series
Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.
research Efficacy and Safety of Baricitinib in Adults with Alopecia Areata: Phase 3 Results from a Randomized Controlled Trial (BRAVE-AA1)
Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
research Alopecias in Humans: Biology, Pathomechanisms, and Emerging Therapies
New treatments for hair loss are emerging as we better understand hair growth and its genetic causes.
research PNKP Is Required for Maintaining the Integrity of Progenitor Cell Populations in Adult Mice
PNKP is essential for keeping adult mouse progenitor cells healthy and growing normally.
research Recent Insight on the Management of Lupus Erythematosus Alopecia
Early treatment of Lupus Erythematosus Alopecia can prevent permanent hair loss, and various medications are effective.
research Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis During Treatment with Tofacitinib: A Case Report
Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
research A Serious Side Effect of a Potentially Widely Used Cosmetic Product
A man developed a serious muscle breakdown condition after using a hair loss medication not known to cause this side effect.
research Alopecia – New Building Blocks
New treatments for hair loss are emerging, and doctors need to learn how to use them effectively.
research Hair Regrowth in a Patient With Central Centrifugal Cicatricial Alopecia After a 2-Month Trial of Baricitinib
A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
research Valproate-Associated Transaminitis and Rhabdomyolysis
Valproic acid can cause muscle damage and liver issues, which improve after stopping the drug.
research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress
Gray hair can potentially be reversed, leading to new treatments.
research Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Areata: A Prospective, Open-Label, Single-Center Study in Asian Arab Population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research Personalized Medicine in the Field of Inflammatory Skin Disorders
Personalized medicine is important for treating skin disorders, with new treatments and connections to hormones and genetics being explored.
research Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.